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The modern clinical research on prostatitis
started with the work of Stamey and
coworkers who developed the basic principles we are still using.
They established the segmented culture technique for localizing
the infections in the males to the urethra, the bladder, or the
prostate and to differentiate the main categories of prostatitis.
Such categories with slight modifications are still used accord-
ing to the NIH classification: acute bacterial prostatitis, chronic
bacterial prostatitis, Chronic Pelvic Pain Syndrome (CPPS) and
asymptomatic prostatitis. Prostatic inflammation is considered
an important factor in influencing both prostatic growth and
progression of symptoms of benign prostatic hyperplasia and
prostatitis. Chronic inflammation/neuroinflammation is a result
of a deregulated acute phase response of the innate immune
system affecting surrounding neural tissue at molecular, struc-
tural and functional levels. Clinical observations suggest that
chronic inflammation correlates with chronic prostatitis/chronic
pelvic pain syndrome (CP/CPPS) and benign prostatic hyper-
plasia (BPH) and an history of clinical chronic prostatitis sig-
nificantly increases the odds for prostate cancer. The NIH-
NIDDK classification based on the use of the microbiological 4-
glasses localization test or simplified 2-glasses test, is currently
accepted worldwide. The UPOINT system identifies groups of
clinicians with homogeneous clinical presentation and is used to
recognize phenotypes to be submitted to specific treatments.
The UPOINTS algorithm implemented the original UPOINT
adding to the urinary domains (U), psycho-social (P), organ-
specific (O), infection (I), neurological (N), muscle tension and
tenderness (T) a further domain related to sexuality (S). In fact
sexual dysfunction (erectile, ejaculatory, libido loss) has been
described in 46-92% of cases with a high impact on the quality
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of life of patients with CP/CPPS. Prostatic ultrasound repre-
sents the most popular imaging test in the work-up of either
acute and chronic prostatitis although no specific hypo-hyper-
echoic pattern has been clearly associated with chronic bacte-
rial prostatitis and CPPS. Use of a digital-processing software
to calculate the extension of prostatic calcification area at
ultrasound demonstrated a higher percentage of prostatic cal-
cification in patients with chronic bacterial prostatitis.
Multiparametric Magnetic Resonance Imaging (mpMRI) is the
current state-of-the art imaging modality in the assessment of
patients with prostate cancer although a variety of benign
conditions, including inflammation, may mimic prostate can-
cer and act as confounding factors in the discrimination
between neoplastic and non-neoplastic lesions. Bacteria can
infect prostate gland by: ascending the urethra, reflux of
urine into the prostatic ducts, direct inoculation of bacteria
through inserted biopsy needles or hematogenous seeding.
Enterobacteriaceae are the predominant pathogens in acute
and chronic bacterial prostatitis, but an increasing role of
Enterococci has been reported. Many strains of these
uropathogens exhibit the ability to form biofilm and mul-
tidrug-resistance. Sexually Transmitted Infections (STI)
agents, in particular Chlamydia trachomatis and Mycoplasma
genitalium, have been also considered as causative pathogens
of chronic bacterial prostatitis. On the contrary the effective
role in genital diseases of other "genital mycoplasmas" is still
a much debated issue. Sexually Transmitted Infections agents
should be investigated by molecular methods in both patient
and sexual partner. “Next generation” investigations, such as
cytokine analysis, cytological typing of immune cells could
help stratifying the immune response. Epigenetic dysregula-
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The modern clinical research on prostatitis started with
the work by Meares EM jr. and Stamey TA and coworkers,
which Stamey nicely summarized 27 years ago (1). Now
we have to see which of their achievements are still valid
and which of them have to be reconsidered or even need
to be replaced by new findings. In summary, Stamey (1)
stated that “Prostatitis” is a common and frustrating prob-
lem for the urologist and the general practitioner. Not
only is there no generally accepted definition, but there
are no clearly established criteria for making the diagno-
sis, and no definite pathophysiology. Because very few
authors have defined prostatitis and almost no two works
use the same criteria for inclusion of patients within a
study, few comparisons can be made from the findings of
one author to those of another. Except for true bacterial
prostatitis, it is fair to comment that little more is known
about prostatitis than was reported by Hugh H Young and
his associates in 1906 (2). Despite this rather pessimistic
view, he and his coworkers developed the basic princi-
ples we are still using. Together with Meares they estab-
lished the segmented culture technique for localizing the
infections in the males to the urethra, the bladder, or the
prostate. Their four glass test results with first voided
urine sample, midstram urine sample, expressed prostat-
ic secretion and first voided urine sample after prostate
massage were used together with the clinical symptoms to
differentiate between the main categories of prostatitis:
acute bacterial prostatitis (ABP), chronic bacterial prostatitis
(CBP), nonbacterial prostatitis, and prostatodynia. In
principle, these categories with slight modifications were
also used for the NIH classifications: 1. Acute bacterial
prostatitis; 2. Chronic bacterial prostatitis; 3. Chronic
Pelvic Pain Syndrom (CPPS); 3a. Inflammatory; 3b. Non-
inflammatory; and 4. Asymptomatic prostatitis (3). In his
review Stamey also presented the principles concerning
pharmacokinetics (PK) of antibiotics used for the treatment
of acute and chronic bacterial prostatitis and the role of
non-ionic diffusion of weak acids and bases across mem-
branes with a pH gradient (1). He and his coworkers
found out, that besides protein binding and lipid solubil-
ity the pH of the prostatic secretion on one side and the
isoelectric point of the compound on the other side were
playing a major role for drug penetration into the prosta-
tic secretion which was considered crucial at least for the
antibacterial therapy of CBP. At that time most studies
were performed in a dog model (1). Thereafter, many PK
studies were also performed in humans, especially with
fluotoquinolones considered the most appropriate antibi-
otics to treat CBP because of their broad spectrum,
including most of the causative pathogens, and because
most fluoroquinolones were neither pure acids nor bases,
but amphoteric (zwitterionic) drugs with an isoelectric
point between the two pKa values (4). Since CPPS on the
tion of inflammatory factors should be investigated according
to systemic and compartment-specific signals. The search for
biomarkers should also include evaluation of hormonal path-
ways, as measurement of estrogen levels in semen.
Antimicrobials are the first line agents for the treatment of
bacterial prostatitis. The success of antimicrobial treatment
depends on the antibacterial activity and the pharmacokinetic
characteristics of the drug which must reach high concentra-
tions in prostate secretion and prostate tissue. Acute bacterial
prostatitis can be a serious infection with a potential risk for
urosepsis
For iInitial treatment of severely ill patients, intravenous
administration of high doses of bactericidal antimicrobials,
such as broad-spectrum penicillins, third-generation
cephalosporins or fluoroquinolones, is recommended in combi-
nation with an aminoglycoside. Use of piperacillin-tazobactam
and meropenem is justified in presence of multiresistant gram-
negative pathogens. The antibiotic treatment of chronic pro-
statitis is currently based on the use of fluoroquinolones that,
given for 2 to 4 weeks, cured about 70% of men with chronic
bacterial prostatitis. For the treatment of Chlamydial prostati-
tis macrolides were shown to be more effective than fluoro-
quinolones, whereas no differences were observed in microbio-
logical and clinical efficacy between macrolides and tetracy-
clines for the treatment of infections caused by intracellular
pathogens. Aminoglycosides and fosfomycin could be consid-
ered as a therapeutic alternative for the treatment of
quinolone resistant prostatitis. Use of alpha-blockers in
CP/CPPS patients with urinary symptoms and analgesics +/-
non steroidal anti-inflammatory drugs (NSAID), in presence
of pain demonstrated a reduction of symptoms reduction and
an improvement of quality of life, although long term use of
NSAID is limited by side effect profile. However, the multi-
modal therapeutic regimen by contemporary use of alpha-
blockers, antibiotics and anti-inflammatory showed a better
control of prostatitis symptoms than single drug treatment.
Novel therapeutic substances for the treatment of pain, such
as the cannabinoid anandamide would be highly interesting to
test. An alternative for the treatment of chronic
prostatitis/chronic pelvic pain syndrome is phytotherapy, as
primary therapy or in association with other drugs. Quercetin,
pollen extract, extract of Serenoa repens and other mixtures
of herbal extracts showed a positive effect on symptoms and
quality of life without side effects. The association of CP/CPPS
with alterations of intestinal function has been described. Diet
has its effects on inflammation by regulation of the composi-
tion of intestinal flora and direct action on the intestinal cells
(sterile inflammation). Intestinal bacteria (microbiota) inter-
acts with food influencing the metabolic, immune and inflam-
matory response of the organism. The intestinal microbiota
has protective function against pathogenic bacteria, metabolic
function by synthesis of vitamins, decomposition of bile acids
and production of trophic factors (butyrate), and modulation
of the intestinal immune system. The alteration of the micro-
biota is called “dysbiosis” causing invasive intestinal diseases
pathologies (leaky gut syndrome and food intolerances, irrita-
ble bowel syndrome or chronic inflammatory bowel diseases)
and correlating with numerous systemic diseases including
acute and chronic prostatitis. Administration of live probiotics
bacteria can be used to regulate the balance if intestinal flora.
Sessions of hydrocolontherapy can represent an integration to
this therapeutic approach. Finally, microbiological examina-
tion of sexual partners can offer supplementary information
for treatment.
KEY WORDS: Chronic bacterial prostatitis; Chronic pelvic pain
syndrome; Inflammation; Antibiotic treatment; Phytotherapy;
Dysbiosis.
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other side was considered a multifactorial disease with
many pathophysiological causes a more symptom related
approach was finally recommended. For this reason the
NIH-CPSI (5) and the UPOINT concept was developed
(6). Many other detailed investigations were performed
thereafter, but not many had a great impact on the clini-
cal practice so far. Unfortunately the management of
CPPS remains still unsatisfactory for the patients as well
as for the urologists.
Role of inflammation and infection in the determinism of
benign prostatic hyperplasia and prostatitis. 
PHYSIOPATHOLOGICAL ASPECTS
(Salvatore Cuzzocrea)
In the spectrum of benign prostatic syndrome (PBS), chron-
ic prostatitis (CP/CPPS) and benign prostatic hyperplasia
(BPH) represent very important pathologies. Prostatic
inflammation is considered an important factor in influ-
encing both prostatic growth and progression of symp-
toms. The common inflammatory/neuroinfalmmatory
aspects in CP/CPPS and BPH are represented by reactive
astrocytes and activated microglia and involvement of
the adaptive immune system, over expression of immune
molecules such as chemokines and cytokines and
increased oxygen and nitrogen reactive species concen-
tration (ROS/RNS). Chronic inflammation/neuroinflam-
mation is a result of a deregulated acute phase response
of the innate immune system effecting surrounding neu-
ral tissue on a molecular, structural and functional levels.
Clinical observations suggest that chronic inflammation
correlates with CP/CPPS and BPH, as prostate tissues
often have infiltrating lymphocytes and macrophages
around glandular elements. The principal therapeutics
for treatment of an enlarged prostate are α-blockers and
5α-reductase inhibitors (5ARIs). Alpha-blockers are
often used as first-line therapy, as they relax muscles in
the prostate and around the neck of the bladder and
facilitate passage of urine but cannot reduce an enlarged
prostate; in addition, these agents have side-effects such
as first dose syncope, dizziness, tachycardia, hypoten-
sion, headache, asthenia, rhinitis and ejaculatory dys-
function. Moreover, cannabinoids have been demon-
strated to exert an important role in the resolution of
inflammation via multiple mechanisms. In the light of
the above, we designed a study to evaluate the anan-
damide congener N- palmitoylethanolamide (PEA) and
the flavonoid polydatin (PLD), as the formulation
m(PEA/PLD), in terms of impact on the inflammatory
process and oxidative stress in BPH. Recently, literature
data reported that PEA, an endogenous fatty acid amide
of the Nacylethanolamine family possess analgesic, anti-
inflammatory and neuroprotective actions, acting at dif-
ferent cellular targets such as immune cells; PEA is clas-
sified as a “Food for Special Medical Purposes” by health
authorities of the European Union member states. PEA
treatment in animals has demonstrated the efficacy and
great promise for its use in the treatment of a lot of dif-
ferent inflammatory disorders. Nevertheless, PEA lacks
direct antioxidant action to counteract free radical devel-
opment as well as DNA, protein and lipid damage which
are important events occurring in BPH. Polydatin (3,4,5-
trihydroxystilbene-3-β-single-D-glucoside), also known
as polygonin, is a polyphenolic phytoalexin with potent
anti-oxidative activity that can be isolated from numer-
ous plant species and can be easily synthesized. 
Our findings led us to assess the therapeutic effects of
oral administration of a composite consisting of co-
micronized PEA + polydatin m(PEA/Pol) in a model of
testosterone-induced benign hyperplasia (BPH) in terms
of its therapeutic effects and efficacy as an anti-oxidant
and antinflammatory drug (7). The results of our study
show, for the first time, that m(PEA/Pol) has the ability
to decrease prostate weight and DHT production in
BPH-induced rats. These effects may be due to the anti-
inflammatory and apoptotic effects of m(PEA/Pol).
Preliminary results suggest that m(PEA/Pol) may exert
therapeutic effect event in a model of CP/CPPS.
Accordingly, these results support the hypothesis that
m(PEA/Pol) should be further explored as a valid candi-
date for the treatment of BPH.
the I2 value. Pooled analysis resulted in a crude odds
ratio of 1.83, indicating a significant association between
a history of prostatitis and prostate cancer (95% CI: 1.43
to 2.35; P < 0.00001) (5). The 1.83 odds ratio could be
converted into a significant risk-ratio estimate of 1.63
(95% CI: 1.23 to 2.17). The set of pooled data showed
considerable heterogeneity (I2 = 91%). Sensitivity analy-
sis performed by excluding an extreme outlier decreased
heterogeneity (I2 = 81%) and resulted in an odds ratio
equal to 1.55 (95% CI: 1.30-1.85,
PROSTATITIS AND PROSTATE CANCER RISK: META-ANALYSIS
(Gianpaolo Perletti)
Inflammation is a major risk factor for several types of
cancer. Conditions like ulcerative colitis, Barrett’s esoph-
agus, chronic urothelium inflammation and hepatitis can
increase the likelihood of developing malignancies. In
the last years, several studies investigated whether a his-
tory of clinical chronic prostatitis can be a risk factor for
prostate cancer. A meta-analysis of such studies, per-
formed on data published up to July 2012 indicates that
clinical prostatitis may be moderately associated with
prostate cancer, since the odds ratio between a history of
prostatitis and prostate cancer was shown to be 1.64
(95% CI: 1.36 to 1.98) (8). After year 2012, new quality
studies have been performed on over 7000 patients (9-
11). Thus, we deemed necessary to perform an updated
meta-analysis to complement the data so far produced,
and to further investigate the relationship between
prostate cancer and previous exposure to chronic pro-
statitis. The main outcome of our systematic review was
the association between a history of clinical chronic pro-
statitis (NIH category II or III) and a histologically con-
firmed diagnosis of prostate cancer of any grade. Out of
2794 de-duplicated records published between year
2000 and January 31st, 2017, we retrieved sixteen full-
text articles reporting the data of fifteen case-control
studies including a total population of 422943 men.
Prostate cancer cases were 13942 (with previous history
of prostatitis, n = 1806) and controls were 409001 (with
229Archivio Italiano di Urologia e Andrologia 2018; 90, 4
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previous history of prostatitis, n = 57203). We analyzed
binary data by calculating odds ratios and 95% confi-
dence intervals (95% CI). We applied a random-effects
model to the analysis of pooled data, and heterogeneity
was assessed by calculating the I2 value. Pooled analysis
resulted in a crude odds ratio of 1.83, indicating a sig-
nificant association between a history of prostatitis and
prostate cancer (95% CI: 1.43 to 2.35; P < 0.00001)
(12). The 1.83 odds ratio could be converted into a sig-
nificant risk-ratio estimate of 1.63 (95% CI: 1.23 to
2.17). The set of pooled data showed considerable het-
erogeneity (I2 = 91%). Sensitivity analysis performed by
excluding an extreme outlier decreased heterogeneity (I2
= 81%) and resulted in an odds ratio equal to 1.55 (95%
CI: 1.30-1.85, P < 0.00001). No significant publication
bias was evidenced by the Egger’s and Begg's tests for
funnel plot asymmetry. The ‘trim and fill’ method
applied to the funnel plot imputed 3 missing studies and
the resulting adjusted estimate of the odds ratio was 2.12
(95% CI: 1.38 to 3.22). Detection bias was virtually pres-
ent in all included studies, mainly due to the increased
probability of prostate cancer detection in prostatitis
patients repeatedly subjected to thorough clinical assess-
ments. Five among the included studies reported data
assessed in 8015 African-American subjects. A subgroup
meta-analysis was attempted, resulting in a non-signifi-
cant crude odds ratio of 1.59 (95% CI: 0.71 to 3.57, P =
0.26). In conclusion, meta-analysis shows that a history
of clinical chronic prostatitis can significantly increase
the odds for prostate cancer. The odds ratio of 1.83, cal-
culated on a larger patient population, is higher than the
one reported by Jiang (OR = 1.6) (8), though association
between exposure to prostatitis and cancer could not be
demonstrated in African-American individuals. 
Conversely, a recent meta-analysis showed a clear associa-
tion in Asian patients (OR = 3.54, 95% CI: 2.60-4.82) (13)
Since – compared with Caucasian men – in men of African
descent the prostate cancer incidence is 60% higher and
the mortality rate is up to 3 times greater, new quality stud-
ies performed on larger sample sizes are urgently needed to
provide unequivocal evidence in this population.
PROSTATITIS: A CONDITION STILL TO BE EXTENSIVELY
INVESTIGATED
(Vittorio Magri, Emanuele Montanari)
Prostatitis is still an enigmatic disease due to the inconsis-
tency of the epidemiological data, the uncertainty etiology,
the inadequacy of the diagnosis and the absence of a stan-
dardized pharmacological treatment. The term prostatitis,
which literally means "inflammation of the prostate", is cur-
rently used to describe a set of clinical conditions of uncer-
tain etiology that are not always associated with a clear
demonstration of the presence of an inflammatory process
and that include painful pelvic symptoms, low urinary
tract symptoms and sexual disorders that require differen-
tiated treatment. The prevalence of these symptoms has
been estimated at 8% of the adult male population (14).
Patients with prostatitis were initially classified into four
groups of acute bacterial prostatitis, chronic bacterial pro-
statitis, chronic bacterial prostatitis and prostatodynia.
From this classification derived the NIH-NIDDK (National
Institute of Health -National Institutes of Diabetes and
Digestive and Kidney Diseases) classification (15), which is
currently accepted worldwide (Table 1). These classifica-
tions are based on the use of the microbiological 4-glasses
localization test of Meares-Stamey or of the simplified 2-
glases test (16, 17). The success of this examination
requires an appropriate collection of the prostatic secre-
tion after adequate prostatic massage.
The UPOINT system identifies groups of clinicians with
homogeneous clinical presentation and is used to recog-
nize phenotypes to be submitted to specific treatments
(Table 2) (18). To improve the clinical approach to pro-
statitis it is crucial to speak a shared language starting from
what is already defined in the guidelines of the European
Association of Urology (EAU) (19) and other national guide-
lines like those of the Prostate Expert Reference Group
(PERG) of the National Health Service (NHS) (20). The
answers of 266 out 1483 (17.9%) urologists associated to
the Società Italiana di Urologia (SIU) who had been sent an
e-mail questionnaire to describe the current methods of
diagnosis and treatment of chronic prostatitis among
Italian urologists showed that a mean of 23 patients with
symptoms of prostatitis presented to their clinics in a
month. The majority of the respondents still prefers the
collection of a narrative clinical history together with the
clinical examination whereas the use of validated ques-
tionnaires is still not widespread. The NIH-CPSI (National
Institute of Health – Chronic Prostatitis Symptom Index) (5)
was administered only by 17.29%. The most frequently
used laboratory tests are the measurement of PSA and the
culture tests of semen and urine. The use of microbiologi-
cal localization tests is still poorly widespread. The most
common instrumental examinations were uroflowmetry
and suprapubic ultrasound. Transrectal ultrasound (TRUS)
is used only by 10%. An extended protocol, such as that
we adopted at our institution, should include: history and
physical examination, administration of symptom ques-
tionnaires (NIH-CPSI, IPSS, IIEF-15 or -5, PEDT, UPOINT
or UPOINTS), microbiological evaluation, prostatic ultra-
sound and uroflowmetry. In particular we suggest the use
of the UPOINTS algorithm that has implemented the orig-
inal UPOINT proposed by Skoskes (18). To the urinary
domains (U), psycho-social (P), organ-specific (O), infec-
tion (I), neurological (N), muscle tension and tenderness
(T) a further domain related to sexuality (S) was added
(21). In fact sexual dysfunction (erectile, ejaculatory, libido
loss) has been described in 46-92% of cases with a high
impact on the quality of life of patients with CP/CPPS. 
In our experience we observed erectile dysfunction in
49.9% (although of mild severity in 75% of cases) and
ejaculatory dysfunction in 59.9% (predominantly burning
or ejaculatory pain and premature ejaculation) (22). 
According to PERG (20) we also suggest to investigate the
presence of irritable bowel syndrome. In fact, in a group
of 232 patients we observed the concomitant presence of
intestinal disorders (diarrhea or constipation, abdominal
pain or bloating) in 69% and 60.5% of patients with
chronic bacterial prostatitis or pelvic pain syndrome,
respectively. Furthermore, the possibility of a sexually
transmitted infection starting from a urethral infection that
spreads progressively to the prostate and to the accessory
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sexual glands has to be considered. Gonococcal infection
is infrequent today, but it is still frequent the finding of
other sexually transmitted pathogens. In our experience
we isolated with the 4-glasses test and/or seminal analysis
Chlamydia trachomatis in 26.8-33.6%, Ureaplasma ure-
alyticum in 56.3-59.7%, Mycoplasma hominis in 7.3% and
Trichomonas vaginalis in 1.4-1.8%. Finally it is recom-
mended to correctly record the results of treatment on the
basis of clinical criteria (NIH-CPSI decrease of at least 4-6
points of the total score or at least 25% decrease of total
score) or of microbiological criteria (eradication, persist-
ence, relapse).
SEXUAL DYSFUNCTION AND CHRONIC PROSTATITIS
(Giuseppe Morgia) 
Chronic prostatitis has an important role in men sexual
function. Sexual dysfunction is difficulty experienced by
an individual or a couple during any stage of a normal
sexual activity. It could be sexual desire disorders, sexu-
al arousal disorder, orgasmic disorders, sexual pain dis-
orders. The prevalence of sexual dysfunctions is: 2-40%
for erectile dysfunction, 15-25% decreased interest or
desire, 8-32% ejaculation dysfunction, 12-19% orgasm,
17% dyspareunia. Prostatitis and sexual dysfunction are
2 common diseases, the prevalence of sexual dysfunction
among men with CP/CPPS was 62%. Among chronic
bacterial prostatitis symptoms one of the most important
symptoms is pain with ejaculation, symptom also pres-
ent among chronic pelvic pain syndrome symptoms,
with erectile dysfunction and premature ejaculation.
Ejaculation pain is one of the most important and fre-
quent chronic prostatitis symptoms, in fact in NIH
Chronic Prostatitis Symptoms Index there is a question
on pain or burning during or after sexual climax. It could
be the only manifestation of prostatitis. 24% of patients
have regularly ejaculatory pain, 50% intermittently and
only 26% of patients with CPPS never experienced ejac-
ulatory pain. There isn’t a single cause of post-ejaculato-
ry pain. Seminal infection, ejaculatory duct obstruction
(with or without stones), neuromuscular spasm instigat-
ed by the muscular constriction of emission, interstitial
cystitis could cause pain during ejaculation. Premature
ejaculation (PE) is male inability to inhibit ejaculation
long enough for the partner to reach orgasm, time before
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Table 1. 
NIH-NIDDK classification of prostatitis.
Category Designation Status of infection
I Acute bacterial prostatitis Acute infection of prostate
II Chronic bacterial prostatitis Recurrent infection of prostate
III Chronic non-bacterial prostatitis/chronic pelvic pain syndrome (CPPS) No demonstrable infection
IIIA Inflammatory WBC in semen/EPS/post-prostatic massage urine
IIIB Non-inflammatory No WBC in semen/EPS/post-prostatic massage urine
IV Asymptomatic inflammatory prostatitis Asymptomatic
WBC: white blood cell, EPS: expressed prostatic secretion.
Table 2. 
UPOINTS classification for phenotypic domains (modified by Shokes et al and Magri et al.).       
DOMAIN DIAGNOSIS TREATMENT
Urinary CPSI urinary score > 4 Anticholinergic
Urgency, frequency or nocturia Alpha-blockers
Post-void residual urine > 100
Psychosocial Clinical history of depression Counseling
Ongoing antidepressant therapy Antidepressant
Evidence of catastrophizing at interview and visits Referral to psychologist
Organ specific Specific prostate tenderness 5-ARI 
Leucocytosis in prostate fluid and/or VB3 Phytotherapy (quercitin, pollen extracts, Serenoa)
Hemospermia Prostatic massage
Extensive prostate calcification Alpha-blockers
Infection Gram neg or Enterococcus in prostate fluid or 4-glass test Antibiotics
Neurological/systemic Pain beyond abdomen or pelvis Gabapentinoids
Irritable bowel syndrome history Antidepressants
Fibromyalgia history Specific treatments
Chronic fatigue syndrome history
Tenderness (skeletal muscles) Palpable muscle spasm or trigger points in abdomen and pelvic floor Skeletal muscle miorelaxants
Pelvic floor physiotherapy
Physical activity
Sexual dysfunction Erectile dysfunction (IIEF questions 1-5 + 15 < 26 PDE5-inhibitors
Orgasmic dysfunction evidence (IIEF 9+10 < 9)
Sexual desire impairment evidence (IIEF questions 11+12 < 9)
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ejaculation varied from 1 to 7 minutes after vaginal intro-
mission. PE is an important sexual dysfunction strongly
associated to CP/CPPS, chronic bacterial prostatitis and
prostatic inflammation. The prevalence of PE among
men with CP/CPPS is 40%. The rates of PE and possible
PE assessed with the premature ejaculation diagnostic tool
(PEDT) significantly increased with an increase in pelvic
pain severity, as assessed by the NIH-CPSI. In the mod-
erate to severe symptom group, 45.0% men demonstrat-
ed PE. In an Italian study of 399 men with symptoms
suggesting prostatitis (23), 220 patients (55%) had ejac-
ulatory dysfunctions, more frequently in patients with
bacterial chronic prostatitis with respect to patients with
chronic pelvic pain syndrome. In particular Chlamydia
trachomatis infection is related to a major incidence of
premature ejaculation in patients with CBP (37.2%),
rather than common uropathogen bacteria (11.5%) (24).
The incidence of erectile dysfunction is increasing with
age, the prevalence of erectile dysfunction among men
with CP/CPPS was 29%. Aetiology of ED in patients with
CP/CPPS could be vasculogenic arterial insufficiency and
veno-occlusive disease, endocrine, neurogenic, psy-
chogenic. In men with chronic prostatitis there is an
arterial stiffness associated with nitric oxide-mediated
vascular endothelial dysfunction and 50% patients have
signs of pelvic floor spasm that decrease arterial penile
inflow. Hypogonadism is a common finding in men with
ED. It has been postulated that sex hormones may also
be an important factor in the development of prostatitis.
Differences have been reported in the frequency of 3 alle-
les near the phosphoglycerate kinase gene between
patients with CPPS and controls, a gene associated to
familiar prostate cancer, hypospadias and specially
androgen insensitivity (25). 
In patients with CP/CPPS there is a higher serum level of
androstenedione and testosterone, with a lower serum
level of cortisol. In 10-19% of patients there are abnor-
malities in the afferent and efferent autonomic nervous
systems associated to neuropathic pain, linked to erectile
dysfunction. At least, CP/CPPs is strongly linked with
stress, anxiety and maladaptive responses to stressful sit-
uation, problems associated with erectile dysfunction.
What kind of therapy we could use for sexual dysfunc-
tion? Unfortunately, there are still few studies in sexual
dysfunction treatment. Alfuzosin 10 mg could be used
for chronic prostatitis, improving IPPS score and bother
score (26), but this alpha-blocker improved sexual func-
tion with lower pain/discomfort and better rigidity and
increased ejaculate. Also use of doxazosin shows a reduc-
tion of NIH-CPSI (27), but demonstrates a not yet clear
role of alpha-blockers for sexual dysfunction in CP/CPPS
patients. Trigger point release and paradoxical relaxation
training of pelvic floor could also have considered in a
multimodal therapy for chronic prostatitis. 
This training shows an improvement in pain, urinary
and sexual scores after therapy, as assessed by Pelvic
Pain Symptom Survey. Phytotherapy represents an
attracting option: treatment with curcumin and
Calendula extract improved significantly IIEF-5 and
PEDT in patients with CP/CPPS type III (28) and
quercetin ameliorated erectile dysfunction in streptozo-
tocin-induced diabetic rats (29).
UTILITY OF ULTRASOUND IN PATIENTS WITH
PROSTATITIS: COMPUTERIZED ANALYSIS
(Matteo Boltri)
Prostatic ultrasound represents the main imaging test in the
work-up of either acute and chronic prostatitis. TRUS and
transperineal (TPUS) approaches are superior to transab-
dominal ultrasound with TRUS being more accurate (30).
Transrectal probes are divided into monoplanar, biplanar
and end-fire according to transducer arrangement. The US
anatomy of apex is well defined by linear probes, whereas
end-fire probes better define the base. Color-Doppler
mode, tissue harmonic imaging and contrast-enhanced
techniques may provide additional information. Utility of
ultrasound in the evaluation of acute prostatitis might be of
clinical interest in the differential diagnosis of parenchymal
abscess (31) or in the detection of a significant post-voiding
volume, which is an indication for temporary bladder
catheterization. The role of ultrasound in the work-up of
chronic bacterial prostatitis (CBP) and chronic pelvic pain syn-
drome (CP/CPPS) is still debated. To date, no specific hypo-
hyperechoic pattern has been clearly associated with CBP
and CP/CPPS. The detection of hypoechoic periurethral
zone volume, posterior prostate lip thickness and bladder
neck thickness might be a hallmark of CP/CPPS (32).
Hyperechoic areas should be described in the ultrasound
report because of their clinical significance. Prostatic calci-
fications are common in the elderly, although younger peo-
ple with CBP and CP/CPPS also develop prostatic calcifica-
tions of varying size, that could be associated with: presence
of a more intense chronic inflammation, positive cultures of
the prostatic fluid, longer duration of symptomatology
according to NIH/CPSI score (33) and lower efficacy of
antibiotic treatment in eradicating the infection of the
prostate (34). For a long time the evaluation of the presence
of prostate calcification has been based on subjective eval-
uations, ending in a qualitative dichotomy between patients
“with” and “without” calcifications. The development of a
standardized method for a quantitative assessment of such
calcification has been advocated. Transrectal images of the
prostate acquired with a standard protocol can easily been
analyzed using a digital-processing software, able to calcu-
late the extension of calcification area. Open-source soft-
ware like ImageJ by NIH are of great importance in making
the access to this technology easier. The relation between
the area of prostatic calcification and the prostate area can
be expressed as a percentage. In a recent study it has been
demonstrated that in a quantitative-based model, a higher
percentage of prostatic calcification is more frequently
observed in patients with chronic bacterial prostatitis and is
related to worse urinary symptoms (35). The utility of an
objective method could be of augmented interest either for
researchers and clinician. 3D transrectal scanners integrat-
ed with a digital-processing software could lead to a better
comprehension of the utility of this procedure.
MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING
OF NEOPLASTIC AND NON-NEOPLASTIC LESIONS
(Pieter J.L. De Visschere)
Multiparametric Magnetic Resonance Imaging (mpMRI)
is the current state-of-the art imaging modality in the
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assessment of patients with suspected or confirmed
prostate cancer (PC). It consists of morphological T2-
weighted images (T2-WI) supplemented with functional
imaging techniques such as diffusion-weighted (DWI)
imaging, dynamic contrast-enhanced imaging (DCE)
and/or MR spectroscopic imaging (MRSI). T2-WI exquis-
itely depicts the prostatic anatomy and pathology. DWI
provides information about the amount of random
movement of water molecules as determined by tissue
density and cell organization. In DCE, the prostate is
repetitively scanned before and during intravenous bolus
injection of contrast agent. MRSI demonstrates the rela-
tive concentrations of the cellular metabolites citrate and
choline in the prostate. 
Poorly differentiated PC can be detected on mpMRI with
high accuracy as it typically appears as a low signal
intensity (dark) lesion on T2-WI, with restricted DWI,
strong contrast enhancement on DCE and high
choline/citrate ratio on MRSI (36). Currently, there is a
trend to treat only patients with clinically significant PC.
In patients with elevated PSA, it is advantageous to per-
form mpMRI of the prostate before a biopsy. When a
suspicious lesion is detected on mpMRI, a targeted biop-
sy can be performed. 
When a suspicious lesion is detected on mpMRI, a tar-
geted biopsy can be performed. When mpMRI is normal,
it has been shown that a biopsy postponed (provided
that the patient is closely followed up), as alternative to
systematic biopsies (37), but the debate is still ongoing
about which strategy should be recommended (38).
Interpretation of mpMRI may however be difficult,
because every prostate exists of a mixture of histological
conditions, which are highly variable in extent and dis-
tribution among patients and some of them may mimic
PC. In our own study (36), we compared a series of
whole-mount radical prostatectomy specimens with the
corresponding mpMRI images. Pure normal prostate
glands are iso-intense on T2-WI and the high signal
intensity areas represent cystic atrophy (CyA) or large-
gland variant of simple atrophy (SA). Due to the high
water content of CyA it can easily be recognized on
mpMRI and PC can be excluded with high certainty.
Inflammation, adenosis, post-atrophic hyperplasia (PAH)
and high-grade prostatic intra-epithelial neoplasia (HG-
PIN) may mimic well differentiated PC on mpMRI
because they all show indistinct low signal intensity on
T2-WI, moderate contrast enhancement on DCE and
slightly decreased citrate concentrations on MRSI (39,
40). On DWI, there is a considerable overlap in imaging
characteristics between inflammation and well-differen-
tiated PC (41). 
The restricted diffusion in (peri)glandular inflammation
may be explained by the high density of inflammatory
cells. Granulomatous prostatitis, a chronic inflammation
that may develop after Bacillus Calmette-Guerin therapy
for bladder cancer, is a well-known mimicker of PC on
mpMRI. A variety of benign conditions may thus mimic
PC and act as confounding factors in the discrimination
between neoplastic and non-neoplastic lesions at
mpMRI. It is the challenging role of the radiologist to
distinguish this multitude of benign or indolent condi-
tions from aggressive forms of PC.
CAUSATIVE PATHOGENS OF BACTERIAL PROSTATITIS
(Alessandra Sensini, Christian Leli)
Any microorganism virtually can cause prostatitis. Bacteria
infect prostate gland by: ascending the urethra, reflux of
urine into the prostatic ducts, direct inoculation of bacte-
ria through inserted biopsy needles or hematogenous seed-
ing. Enterobacteriaceae, especially Escherichia coli, are the
predominant pathogens in acute and chronic bacterial pro-
statitis, but an increasing role of Enterococci has been
reported (42, 43). Many strains of these uropathogens
exhibit the ability to form biofilm, which can be responsi-
ble of the treatment failure. Moreover, the emergence of
multidrug-resistant organisms, mostly by means of extend-
ed-spectrum beta-lactamases, AmpC beta-lactamases and
carbapenemases for Enterobacteriaceae, vanA gene for
Enterococci and mecA/mecC genes for Staphylococcus
aureus, make antimicrobial therapy very challenging.
Fungal etiology is generally limited to patients with
impaired immunity. Sexually Transmitted Infections (STI)
agents, in particular Chlamydia trachomatis, have been also
considered as causative pathogens of chronic bacterial pro-
statitis (44). Due to the improvement of diagnostic tech-
nologies, recent studies supported the etiologic role of
Mycoplasma genitalium, a cell wall-deficient small bacteri-
um belonging to the Mycoplasmataceae family, as a true
causative pathogen of STI and possibly of prostatitis.
Under the designation "Genital Mycoplasmas" are included
other species, Mycoplasma hominis, Ureaplasma parvum
and Ureaplasma urealyticum. They are considered com-
mensals of the lower female genital tract, indeed are fre-
quently recovered from genital samples in asymtomatic
subjects. Their effective role in genital diseases of both
women and men is still a much debated issue. Likewise, if
chronic prostatitis/chronic pelvic pain syndrome is really
an infectious disease is still doubtful (45, 46).
MICROBIOLOGICAL DIAGNOSIS
AND MICROBIOLOGICAL PROTOCOL PROPOSALS
(Maria Agnese Latino, Alessandra Sensini, Christian Leli)
Microbiological diagnosis is imperative to identify the
etiologic agent of prostatitis (19, 20, 47-49). The mid-
stream specimen of urine (MSU) is the sample of choice to
test in acute bacterial prostatitis. In presence of clinical
signs suggestive of a blood-stream infection, a blood cul-
ture should be taken. The traditional Meares-Stamey 4-
glass test is recommended for the diagnosis of chronic
bacterial prostatitis. The 2-glass test (also called Nickel
test) is an acceptable alternative. The analyses of data
collected by a questionnaire sent to italian urologists
showed that a higher number of seminal fluid cultures
than Meares-Stamey test were performed for diagnosis of
chronic bacterial prostatitis. Semen culture is not recom-
mended by the European guidelines because of low
specificity due to possible contamination by urethral and
skin bacteria. Moreover, a diagnostic cut-off in colony
count for symptomatic patients has not been deter-
mined. Semen culture can be used for diagnosis in addi-
tion to Meares-Stamey test as 5th glass and results com-
pared to the other samples. If used alone, it should be
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preceded by a first 10-mL void as urethral specimen. All
samples should undergo microscopic examination for
the presence of leukocytes, culture for isolation of Gram-
negative or Gram-positive bacteria and/or fungi and bac-
terial count, reporting also small numbers of colonies. In
case of positive cultures, antimicrobial susceptibility test-
ing should be performed, according to EUCAST rules.
Sexually Transmitted Infections agents should be inves-
tigated by molecular methods (test of choice) in both
patient and sexual partner.
ANALYSIS OF TOTAL EJACULATE IN THE DIAGNOSTIC
EVALUATION OF BACTERIAL PROSTATITIS
(Vittorio Magri) 
The possible diagnostic role of the microbiological exam-
ination of the seminal fluid is still controversial, due to
the possible contamination of the fluid in the urethral
passage and the presence of secretions from accessory
glands (seminal vesicles, bulbo-urethral glands of
Cowper and urethral of Litrrè).
The EAU guidelines (19) exclude the use of semen culture
in the diagnosis of chronic prostatitis, although the rec-
ommendation strength is weak, and the PERG (20) does
not mention this test. On the other hand, in the
NIH/NIDKK classification (16), microscopic examination
of the seminal fluid in the definition of non-inflammatory
CPPS (IIIb) and asymptomatic prostatitis (IV) is envis-
aged. Furthermore, Stamey himself (1) has argued that
semen cultures may be likely reliable for the identification
of Gram negative infections and other authors have con-
sidered the use of this investigation if associated with a
collection of urine VB1 (first voiding) and VB2 (mid-
stream) or when it is not possible to obtain the expressed
prostatic secretion (EPS) sample with prostate massage (50,
51). In our experience in 81.7 and 99.9% of patients with
chronic bacterial prostatitis and CP/CPPS respectively it
was not possible to obtain an EPS sample and that the
examination of the seminal fluid in patients with CBP
allowed to demonstrate the presence of Gram negative
more frequently than in VB3 or EPS (52).
In a 565 series of samples with positive microbiological
tests of seminal fluid and/or Meares-Stamey test samples
284 patients (52%) had a positive semen test in the pres-
ence of negative Meares-Stamey test, 153 (27.1%) negative
seminal examination and Meares-Stamey positive test and
118 (20.9%) positive concordance of the two tests.
These data agree with a previous study that showed that
the semen examination is positive in 78.6% of samples of
patients with chronic bacterial prostatitis and in no case
of CP/CPPS.
This observation confirms what was said by Nickel (53)
that observed that the culture of the seminal fluid
increased the number of patients classified as category II,
even in the absence of precise evidence of the literature
and data that demonstrate a clinical improvement after
antibiotic treatment of patients with positive culture of
seminal fluid. Subsequently, however, some numerically
consistent studies (54, 55) have confirmed that the
examination of the seminal fluid may be a good indica-
tor of prostatic infection when the semen was analyzed
together with the 4-glass test and a study showed a pos-
itive response after antibiotic treatment of infections
diagnosed with semen examination.
Finally, the examination of the seminal fluid allows the
identification of atypical sexually transmitted pathogens
in high percentages (50% of cases with Chlamydia infec-
tion and 73% of cases infected with Ureaplama ure-
alyticum and Mycoplasma hominis.
In conclusion, the microbiological examination of the
seminal fluid may present a useful integration of the
results of the Meares-Stamey test.
ROLE OF BIOFILMS: PATHOGENESIS
AND THERAPEUTIC IMPLICATIONS
(Tommaso Cai)
Chronic bacterial prostatitis (CBP) is diagnosed by clinical
symptoms and microbiological analysis by using biolog-
ical samples from Meares-Stamey test; treatment with
appropriate antibiotics is usually prescribed, in line with
the European Association of Urology (EAU) guidelines
(42). Several times, fluorquinolones are considered
drugs of choice to treat patients with CBP, regardless of
a bacterial isolation. Antibiotic treatment usually
improves the clinical symptoms, although short-term
recurrences are reported frequently (56). It is probably
due to the incomplete eradication of the causative
pathogens, by phenotypical antibiotic resistance at the
site of infection and/or lack of antibiotic penetration into
prostate tissue. On the other hand, antimicrobial treat-
ment is most effective in acute infection when bacteria
are in the ‘planktonic’ state, before they form biofilms.
The role of biofilm-producing bacteria in development of
acute and chronic prostatitis have been recently dis-
cussed. Bacteria living in a biofilm usually have signifi-
cantly different properties compared with free-floating
bacteria (planktonic) of the same species, as the dense
and protected environment of the film allows them to
interact in various ways (57). They benefit in this envi-
ronment by an increased resistance to antibiotics, as the
dense extracellular matrix and the outer layer of cells
protect the interior of the community. Moreover, it is
well demonstrated that biofilm persisting bacteria, which
are usually adherent to tissue surfaces through their own
fimbriae and slime, represent the main limitation of
antibiotic efficacy and the potential site of short-term
infection recurrences. Recently, Bartoletti and Cai
demonstrated that biofilm-producing bacteria were com-
monly found in CBP patients and had a significant nega-
tive impact on the clinical response to antibiotic therapy
(58). Moreover, they demonstrated that the relief of
symptoms seemed to be much more inversely related to
the bacterial biofilm production than to apparent nega-
tive microbiological tests after treatment. On the other
hand, Cai et al. focused their attention on the role of bac-
terial biofilms in the genesis of prostate calcifications,
suggesting a possible role of bacterial biofilm in the gen-
esis of prostate calcifications and in the development of
symptoms in chronic prostatitis (59). In this sense the
role of prostate calcifications should be reconsidered.
Prostate calcifications are not only a sonographic sign of
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previous prostatitis but should be considered a locus for
difficult-to-treat bacteria (organized in a biofilm and
having the potential to persist after common antibiotic
treatments) within the prostate tissue. The presence of a
bacterial biofilm represents a chronic inflammatory stim-
ulus that could lead to the development of symptoms
related to the grade of inflammation and the immune
response of the patients. In the case of high-grade
inflammation, the patient could report urinary or pelvic
pain. The fluctuating symptomatology reported by the
majority of patients might be explained by variation in
the inflammatory response to the development and mat-
uration of the bacterial biofilm (59). The antibiotic treat-
ment is probably effective in mitigating the grade of the
infection but is not fully effective in eradicating the bac-
terial biofilm. Future studies should be designed to
explore whether effective eradication of the bacterial
biofilm could be associated with a good medium- and
long-term clinical outcome of treatment.
RESISTANCE OF GERMS TO ANTIBACTERIAL DRUGS
IN PATIENTS WITH CHRONIC BACTERIAL PROSTATITIS
(CBP): THE HELLENIC EXPERIENCE
(Konstantinos Stamatiou, Nektaria Rekleiti, Vaia Papadouli)
CBP is a very common and highly bothersome urologic
condition. It remains poorly understood (14, 60, 61).
Despite progress in its management, many cases are
undertreated and a significant number relapse . The rea-
sons are practically unknown and include host, bacterial
and treatment-related factors. Inappropriate treatment,
incomplete treatment and increased resistance of respon-
sible bacteria to antibiotics have been proposed to con-
tribute most (62-65). While the two first conditions can
be easily rule out, the hypothesis of alteration of drug
resistance patterns of responsible bacteria remains rela-
tively unclarified. 
We planned a study to retrospectively investigate the
resistance of microbes to antibacterials in patients with
chronic bacterial prostatitis that had as secondary objec-
tive to determine whether the resistance of pathogens
increases in patients with CBP recurrence. We studied
bacterial isolates from urine and/or prostatic secretions
or sperm cultures obtained from individuals with CBP
visiting the prostatitis clinic of our department since its
establishment (03/2009). Patients underwent the
Meares-Stamey test (a few cases underwent the 2-glass
test). Depending on medical history and specific symp-
toms, urethral smear and sperm cultures were addition-
ally obtained from several patients. Those presenting
with febrile prostatitis were investigated by a midstream
specimen of urine culture (MUC) only. Samples from
patients diagnosed with chronic prostatitis for the first
time were compared with those of patients with a histo-
ry of chronic prostatitis and previous antibiotic treat-
ment. The Meares-Stamey test was considered positive
when: 1) bacteria grew in the culture of the EPS and
VB3/PoPM (post-prostate massage) urine sample but not
in VB1 and VB2/PrPM (pre-prostate massage) sample; 2)
bacterial colonies in VB3 were higher than that of VB1
and VB2 samples. Given that no standard cut-off level of
the number of bacteria in both urine and prostate secre-
tion samples exists for the diagnosis of chronic bacterial
prostatitis, we defined no lower acceptable level for
either one. Bacterial identification was performed using
the Vitek 2 Compact system and susceptibility testing
was performed by disc diffusion and/or the Vitek 2 sys-
tem. Interpretation of susceptibility results was based on
Clinical and Laboratory Standards Institute (CLSI)
Guidelines. Recorded demographical data and medical
history of the patients were revised: patients suffering
from conditions affecting either bacterial virulence or
host response (eg. immunodeficiencies, abnormalities of
the urogenital system) and individuals who received
antibiotics or immunosuppressive treatment within 4
weeks from the visit were excluded from the study. 
The statistical analysis was performed using Fisher’s exact
test of significance. The accepted level of significance in
this study was 0.05 (p value < 0.05 is significant). The local-
ly appointed Ethics Committee approved the research pro-
tocol. A total of 548 bacterial isolates obtained from the eli-
gible patients in 1324 visits owing to CBP recorded over a
6-year period (03/2009-05/2015) were analyzed. 
In 114 cases the number of colonies was quite similar in
both VB2/pre-PPM and VB3/post-PPM cultures. These
cases were excluded from the study. In addition 44 cases
with negative cultures (despite presence of bacteria in
EPS/VB3/post-PPM) were also excluded from the study as
possibly false negative since no previous antibiotic intake
was reported. The remaining 390 out of 548 bacterial iso-
lates diagnosed as CBP finally consisted the material of the
study. Of them, 253 (44 EPS/sperm and 209 VB3/PPM)
were from patients diagnosed with CBP for the first time
(group A) and 137 (42 mid-stream urine, 51 EPS/sperm
and 44 VB3/PPM) were from patients with a history of CBP
and previous antibiotic treatment (group B) (Table 1 in
Supplementary Materials). The most frequent pathogen -in
both groups was E. coli. Other frequent types were
Coagulase negative Staphylococci (hominis & haemolyticus)
and Enterococcus spp. The overall frequency of gram (+) was
greater than that of gram (-). Of note, bacterial frequencies
were similar in both groups (A and B) (Table 2 in
Supplementary Materials). Most cases were found with one
type of bacteria from each isolate (monomicrobial) howev-
er several cases in both groups (49 & 43) were identified
with more than one type of bacteria from each isolate
(polymicrobial) (Table 3 in Supplementary Materials).
Regarding clinical relapses, pathogens most commonly
associated were Enterococcus faecalis, Staphylococcus CoN
and E coli. The mean time interval between chronic prosta-
titis relapses was 13.9 months (minimum 2 and maximum
56 months). In sperm cultures, in both groups,  the most
frequent isolate was Enterococcus faecalis (13 and 8
respectively). A remarkably higher Enterococcus faecalis
isolate resistance was noticed in group B (69% vs 25%)
(Table 4 in Supplementary Materials).
In urethral cell/discharge cultures Staphylococcus CoN
and Clamydiae trachomatis were the most common
pathogens in both groups (Table 4). Generally, a rela-
tively increased resistance to quinolones was observed
and a sufficient degree of susceptibility to the least used
antibiotics (TMP-SMX, tetracyclines, aminoglycosides,
penicillins, and macrolides) (Table 5 in Supplementary
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Materials). In some cases cross resistance between
ciprofloxacin and newest quinolones was not observed.
The nature of this study explain the high rate (41.3%) of
positive Meares-Stamey and/or 2-glass tests, however,
combined with the fact that no cut-off level of the num-
ber of bacteria in both urine and prostate secretion sam-
ples was used for the diagnosis of CBP may indicate a rel-
ative high underdiagnoses rate. The low number of
assessable EPSs in this study may indicate the need of
better preparing (e.g. abstain from sexual intercourse for
3 to 5 days before S/M test). In confirmation to the
above, the number of assessable EPSs in Group B was
greater probably because of the familiarization of
patients of Group B with the examination process. 
The proportion of Gram-positive isolates in the current
study is high. The reason explaining the above fact is
unknown however it may be associated with the better
understanding of the role of Gram-positive bacteria in the
development of the disease and the consequent awareness
of clinicians and laboratory assistants. The rate of polymi-
crobial isolates was significantly higher in group B than in
group A (31% vs 19%). The interpretation of this finding
is twofold: on one hand it is possible that repeated antibi-
otic treatment reveals participating microbial members of
prostate biofilm and in the other hand may suggest a
chronic decline of the immune system function.
Our finding of increased resistance to quinolones has
been previously described. Combined with the finding of
sufficient degree of susceptibility to the least used antibi-
otics this fact can be easily attributed explained by the
over-prescription of quinolones in our country . High
resistance rates of Enterococci strains may reflect its
intrinsic resistance to antibiotics. Of note, differences in
susceptibility between Enterococci strains in monomicro-
bial isolates and polymicrobial isolates may be explained
by genomic interactions.
Notably, the coexistent urethral infection found in
patients of both groups indicates the continuity of the
infection of the genitourinary tract system4. In addition,
the fact that the findings from sperm cultures were com-
parable to those of EPS and post PM cultures supports the
supplementary role of sperm cultures to the Meares-
Stamey test. Finally, the wide variation in the number of
colonies, the presence of different microorganisms in the
same culture as well as the presence of CoN Staphylococcus,
strengthen the newer appreciation of chronic prostatitis as
a biofilm disease.
In conclusion, given the regional variation of the distri-
bution of uropathogens and their susceptibility pattern
to antibiotics, knowledge of the susceptibility of
causative microorganisms to various antibiotics is neces-
sary in order to select the optimal treatment thus pro-
viding better eradication rates and make the creation of
drug-resistant strains less likely. 
MEDICAL TREATMENT OF CHRONIC BACTERIAL PROSTATITIS
(Alberto Trinchieri)
Chronic bacterial prostatitis (CBP) is a clinical entity
defined by the isolation of bacteria in the prostatic secre-
tion that according to National Institutes of Health -
National Institute of Diabetes and Digestive and Kidney
Diseases (NIH - NIDDKD) criteria is classified as catego-
ry II. The use of sequential bacteriologic localization cul-
tures represents the most accurate method for diagnos-
ing CBP. The most common organism associated with
CBP is Escherichia coli, although infections with
Klebsiella, Enterobacter, Proteus, Pseudomonas, and ente-
rococci have also been documented (66). In CBP patients
biofilm-producing bacteria were frequently demonstrat-
ed as an explanation of the unsatisfactory response to
antibiotic therapy (58). Antimicrobials are the first line
agents for the treatment of CBP (67). The success of
antimicrobial treatment of chronic bacterial prostatitis
depends on the antibacterial activity and the pharmaco-
kinetic characteristics of the drug which must reach high
concentrations at the site of infection, that is prostate
secretion and prostate tissue (68).
Diffusion of antibiotics in prostatic secretion/tissue
To penetrate the prostatic epithelium, the drug must be
lipid soluble, have minimal binding to serum protein
and favorable size, shape and degree of ionization in
order to diffuse across biological membranes in presence
of a pH gradient (considering that ionized molecules do
not cross epithelial membranes). The acid molecules
reach greater concentrations in the plasma (pH 7.4) and
the basic ones in the acidic prostatic fluid. Beta-lactam
drugs have a low pKa and poor lipid solubility, and thus
penetrate poorly into prostatic fluid; macrolides, tetracy-
clines and trimethoprim are bases showing excellent
penetration into prostatic fluid and tissue. 
Fluoroquinolones are amphoteric and have a more com-
plex behavior acting either as zwitterions or neutral mole-
cules depending on the medium. Experimental results in
the dog confirm this tendency (Table 1 in Supplementary
Materials). Experimental animal studies are not easily
transferred to the human clinic because the pH of the pro-
static secretion in humans is less acidic and it is increased
in chronic prostatitis. Evaluation of tissue concentrations
of antimicrobials measured on samples coming from
endoscopic prostate resections after antibiotic administra-
tion confirms the good penetration of fluoroquinolones in
prostatic tissues (Table 2 in Supplementary Materials).
Clinical results of antibiotic treatment in CBP
Before 2000 there are only few randomized studies on
the use of non-quinolone drugs in the treatment of CBP,
the studies are underpowered so it is difficult to draw
conclusions on the effectiveness of these treatments
(Table 3 in Supplementary Materials). 
In patients with CBP treated with trimethoprim/sul-
famethoxazole (TMP/SMX) cure rates of 0% to 71% were
reported. When treatment was prolonged for over a 12-
week period the cure rate was about 40%. Tetracyclines,
especially doxycycline and minocycline, and macrolides
have been extensively used to treat CBP. In a RCT
minocycline demonstrated better microbiological (45 vs
21%) and clinical (65 vs 46%) cure rates than cephalex-
in. In a small series, use of carbenicillin indanyl sodium
has been associated with cure clinical and microbiologi-
cal rates of 93 and 75% respectively and a RCT of CBP
treatment demonstrated similar cure rates of carbeni-
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cillin and ofloxacin. Amoxicillin-clavulanic acid or clin-
damycin were used to treat patients with prostatic infec-
tion resistant to empirical treatment with quinolones
(50% anaerobic bacteria). In more recent years the
antibiotic treatment of CBP was mainly based on the use
of fluoroquinolones that, given for 2 to 4 weeks, cured
about 70% of men with CBP due to their broad antibac-
terial spectrum and efficient distribution to the prostate
tissue and glandular ducts (Table 4 in Supplementary
Materials). Fluoroquinolones are generally well tolerated
but In some patients prolonged use of quinolones may
be contraindicated due to potential adverse effects in
presence of various contraindications (history of ten-
donitis or long QT syndrome).
Randomized clinical trials
The meta-analysis of Perletti et al. took into consideration
the RCTs published between 1966 and 2012 (69).
Authors concluded that for the treatment of traditional
pathogens the different fluoroquinolones used in the
treatment of CBP have equal microbiological and clinical
efficacy. The rate of adverse events of treatment also
appeared to be equivalent. On the contrary, for the treat-
ment of Chlamydial prostatitis macrolides were shown to
be more effective than fluoroquinolones, both microbio-
logically and clinically. No differences were observed in
microbiological and clinical efficacy and adverse effect
between macrolides and tetracyclines for the treatment
of patients with CBP caused by intracellular pathogens,
both Chlamidial and Mycoplasma (Table 5 in
Supplementary Materials). 
Alternative antibiotic regimens 
The increased emergence of bacterial resistance and the
decline in newly developed antibiotics are limiting the
armamentarium for the treatment of CBP. The possible
options to counteract this problem are the increase in the
dosage of the antibiotics already in use, the combination
of antibiotics and the reintroduction of “old” antibiotics
that were previously abandoned or not used for the treat-
ment of CBP (Table 6 in Supplementary Materials).
Aminoglycosides diffuse in the prostatic tissue and fluids
although less than other antibiotics and in previous
years, some aminoglycosides, such as kanamycin and
streptomycin were successfully used in small series of
patients with CBP. A recent larger study of the adminis-
tration of aminoglycosides alone or in combination with
a β-lactam antibiotic showed microbiological eradication
and clinical remission in 79% of patients. Genetic testing
of patients for mutations predisposing to sensorineural
deafness allowed safer administration of aminoglyco-
sides. Orally absorbed fosfomycin trometamol has also
been proposed for the treatment of CBP because of its
good penetration in prostatic tissue. A recent review
found two small series and two case reports of patients
with CBP treated with fosfomycin after treatment failure
with fluorquinolones and TMP/SMX (70). Fosfomycin
was administered orally (3 grams every 48 or 72 hours)
for periods of 2 to 6 weeks, although in some critical
cases it was administered for longer periods of up to 16
weeks. In the two series, microbiological cure rate > 50%
and of clinical cure rate of 50-77% were reported. The
results of these studies suggest that aminoglycosides and
fosfomycin could be considered as a therapeutic alterna-
tive for the treatment of quinolone resistant CBP
although their use should be still validated by random-
ized-controlled studies. An another option to improve
the success rate of antibiotic treatment of CBP is the asso-
ciation of two antibiotics. In particular, macrolides can
be associated with quinolones to exploit their ability to
reduce biofilms growth. Combination treatment of
ciprofloxacin and azithromycin showed a 64.2% micro-
biological eradication rate after a 6-week cycle of thera-
py that reached 83.9% after a second 6-week cycle in
patients showing persistence of infection or reinfection at
the end of the first cycle of treatment. Combination treat-
ment showed high eradication rates of infection by both
traditional uropathogens and unusual pathogens. An
higher dose of ciprofloxacin (750 mg/daily) in combina-
tion with azithromycin (500 mg, thrice-weekly) for 4
weeks showed enhanced eradication rates and lower
inflammatory white blood cell counts compared to a 500
mg/daily dose for 6 weeks. 
Locally injected antimicrobial drugs 
Local injection of antibiotics into the prostate has been
reported to be effective although no RCT validated this
modality of treatment The potential advantage of direct
injection into the prostate should be to bypass the pro-
static capsule to allows use of antimicrobials that are not
easily concentrated in the prostatic tissue after oral
administration. Small case series showed encouraging
results and a small RCT (50 men with prostatic secre-
tions sensitive to amikacin) demonstrated that anal sub-
mucosal injection of amikacin for 10 days significantly
improved clinical and bacteriological cure rate at 3
months in comparison with intramuscular injection for
the same period. 
Adjuvant treatment with herbal products and probiotics 
A few RCTs on adjuvant treatment with herbal products
(mainly Serenoa repens extract) and probiotics have been
published (Table 7 in Supplementary Materials) The
combination treatment was able to improve the clinical
(and in some studies the microbiological efficacy) of
prulifloxacin in patients affected by CBP. In patients with
CBP and irritable bowel syndrome a prolonged treatment
with rifamixin and probiotics was effective in lowering
the progression of prostatitis into more complicated
forms of male accessory gland infections. 
Length of treatment
The optimal duration of antibiotic treatment for CBP has
not been defined by controlled trials, although a study
demonstrated the superiority of a 12 week TMP/SMX treat-
ment with respect to a 10 day course of the same antimi-
crobial agent. However a minimum duration of antibiotic
treatment of 4 weeks should be considered. In a RCT clin-
ical success at the 6-month follow up of levofloxacin 750
mg/day for 2 or 3 weeks was inferior to the standard ther-
apy with levofloxacin 500 mg/day for 4 weeks (71).                                                        
Chronic oral antibiotic suppression has been proposed
to reduce or eliminate bacterial growth in the urine in
order to limit the urinary symptoms of the disease. A
chronic suppression approach only mandates adequate
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drug levels in the urine and does not require penetrance
of the prostate, thus many antibiotic choices with a safer
side effect profile are available, such as nitrofurantoin
and cephalosporins. Low-dose trimethoprim (50 or 100
mg once daily), trimethoprim-sulfamethoxazole (40 and
200 mg once daily), and nitrofurantoin (50 or 100 mg
once daily) are remarkably effective for this purpose.
BACTERIAL RESISTANCE: WHICH ANTIBIOTICS TO USE? 
(Valentina Marchese, Alberto Matteelli)
Enterobacteriaceae are the most common cause of either
acute or chronic prostatitis. Resistance to fluoro-
quinolones, considered the drug of choice for the man-
agement of prostatitis, has been increasing since 2000
(72). The progressive increase in fluoroquinolone resist-
ance is also associated with the spread of extended spec-
trum β-lactamase (ESBL), which are enzymes that confer
resistance to most beta-lactam antibiotics with the excep-
tion of carbapenems and, in some selected cases, beta-
lactam/beta-lactamase inhibitors (70). These enzymes
are frequently associated with the expression of addi-
tional genes harboring resistance to other antimicrobial
classes, such as fluoroquinolones and aminoglycosides
(73). Treatment of acute and chronic bacterial prostatitis
represents always a challenge, as only few antimicrobials
reach therapeutic concentrations in the prostate (72).
High lipid solubility, a low degree of ionization, a high
dissociation constant (pKa, allowing diffusion of the
unionized component into the prostate), low protein
binding, and small molecular size enhance molecular
penetration within prostate (72). Only a limited number
of agents adopted for infections due to multi-drug resist-
ant (MDR) gram-negative bacteria (showing resistance to
at least three different classes of antimicrobials) have
these characteristics (72). In some cases, even if limited
pharmacokinetic data available, they have been
described to be effective in treating prostatitis (72). For
severely ill patients, empirical coverage for MDR bacteria
should be provided in presence of risk factors such as
hospitalization, recent use of fluoroquinolones and/or
beta-lactams, immunosuppression, recent invasive pro-
cedures (73). In all other cases, especially in chronic pro-
statitis, antimicrobial treatment should be guided by
drug susceptibility test (DST). Whenever possible outpa-
tient treatment should be preferred, but the majority of
antibiotics for MDR bacteria require parenteral adminis-
tration. Studies on site-specific pharmacokinetic and
pharmacodynamic of piperacillin-tazobactam and
meropenem justify their administration in susceptible
gram-negative prostatitis (74, 75). Prostate tissue pene-
tration of colistin has not been studied and should pos-
sibly not be used. Tigecycline undergoes minimal uri-
nary excretion and is usually not considered the first
choice for susceptible MDR gram-negative bacteria in
urinary tract infections. Nevertheless, few case reports
describe the utilization of tigecycline in susceptible
strains, with variable clinical and microbiological out-
comes (76). So far, Fosfomycin seems the most interest-
ing drug for its susceptibility profile, prostate penetra-
tion and availability of oral administration. In patients
with bacterial prostatitis caused by antimicrobial-resist-
ant E. coli, oral fosfomycin has shown clinical cure rates
of 50-77% and microbiological eradication rates above
50% (70). Ceftolozane-tazobactam and ceftazidime-
avibactam are two novel drugs which have been intro-
duced for the management of MDR gram-negative infec-
tions. At the moment, there are no data on their utiliza-
tion and penetration in prostate tissues. However, based
on previously available data on cephalosporins prostate
penetration, both are unlikely to be considered the pri-
mary choice in prostate infections, but further studies are
needed to assess their possible role in this clinical setting. 
ANTIBIOTIC-RESISTANCE, A PUBLIC HEALTH PROBLEM
(G. Maierna)
The problem of antibiotic resistance poses some questions.
1) When did it become a public health problem? 2) What
is the answer of scientific societies to this problem? 3) How
civil society deals with antibiotic resistance? In the 40s,
shortly after the introduction of the antibiotic into the ther-
apeutic armamentarium of the clinicians, there appeared
the first bacterial resistance. From the 60s onwards it has
been a progressive and constant increase of antibiotic
resistances that has been overcome with the use of new
molecules that were periodically synthesized and market-
ed. In the last decades it is no longer like that. The antibi-
otic resistance is still increased and many bacterial strains
also became multi-resistant to various antibiotics (77-81).
This modification of the bacterial ecosystem has been
accompanied by progressive abandonment of the research
for new anti-infective by most pharmaceutical companies.
Meanwhile the ecosystem has further changed and not
only for the use and abuse of antibiotic therapy in the
human field but also for the spread in the veterinary, zoo-
technical and aquaculture sectors. All this brought to
recent finding of infections related to bacteria that are less
sensitive to antibiotics available and always more often
multi-resistant, if not even resistant to all the antibiotics
tested and available. At this point the diffusion of bacterial
resistance has so spread to make the phenomenon no
longer a problem limited to some clinical cases to be treat-
ed in hospital but a global threat that we have to consid-
ered as a public health problem. In this last decade, in par-
ticular, it has started a run to find solutions (at least so
hopefully). The alternative is a return to the pre-antibiotic
era when there were no suitable drugs to treat most infec-
tions. Of course, now there are the alarms of the scientific
and health world to combat the phenomenon but the reac-
tion of the political authorities and civil society is still ongo-
ing. The G20 of Health, held in Argentina in 2018, like
many other international meetings, confirmed the "One
Health" plan presented in May 2015 at the 68th World
Assembly WHO. Everyone agrees for this global and syn-
ergistic action at world and national level promoting a col-
laborative and inter-sectorial commitment among the vari-
ous operators of human and veterinary medicine, agricul-
ture and food production and consumers. It is crucial to
increase the level of awareness that a prudent and respon-
sible use of antibiotics is necessary in order to counteract
antimicrobial resistance that is a growing threat involving
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infections caused by bacteria, fungi, parasites, viruses to
determine a progressive a reduction of efficacy of antibac-
terial, antifungal, antiparasitic and antiviral chemothera-
peutic drugs. At this point the treatment of patients with
infection becomes difficult, expensive and often impossi-
ble. For the most fragile, immunocompromised, and elder-
ly this results in a prolongation of the disease, and in the
hospitalization and always more often an increase in mor-
tality. In the "One Health" program of the WHO the objec-
tives to be pursued are: improve awareness of antimicrobial
resistance; reinforce knowledge with surveillance and
research; reduce the incidence of infections; optimize the
use of antimicrobial drugs; develop the necessary invest-
ments with adequate financial support. Also in September
2015 the European Parliament approved a resolution for the
development of "One Health" in human and animal health
to limit multi-resistance to antimicrobials in these areas. At
European level, the European Center for Disease Prevention
and Control (ECDC), with its own specific prevalence stud-
ies conducted among 2011 and 2017 identified as a sig-
nificant problem of public health related Infections assis-
tance and antimicrobial resistance. Various microorgan-
isms, taken into consideration for their characteristics of
pathogenicity, resistance and epidemiology, are considered
in these years a real emergency for their ability to resist the
action of different antimicrobial agents with various resist-
ance mechanisms. The American Society of Infectious
Diseases (IDSA) in 2008 hasgrouped six pathogens in the
acronym ESKAPE from the initials of their names:
Enterococcus spp, Staphylococcus aureus, Klebsiella pneumoni-
ae, Acinetobacter baumannii, Pseudomonas aeruginosa,
Enterobacter spp. The CDC quantified in 2008-2011 an
annual number of infections supported by ESKAPE equal
to 130,000 cases with 15,000 related deaths. This evalua-
tion proved to be just outdated for the period 2011-2017
when some microbial species, endowed with complex
resistances, have shown an increase in their epidemic
impact with resistance phenotypes more difficult to treat
while other microbial species, not included in the ESKAPE,
have become clinically relevant as Streptococcus pneumoni-
ae, Neisseriae gonorrhoeae, Clostridium difficilis and Candida
spp. In hospitals, infections caused by antibiotic-resistant
bacteria are now associated with greater morbidity and
mortality as well as a longer hospitalization, compared to
infections by susceptible bacteria. Every year in the world,
the antibiotic resistance determines 700,000 deaths of
which 25,000 in Europe with a cost of 1.5 billion euros. If
the antibiotic resistance will remain at current levels of
growth, the deaths could reach 10 million in 2050. For
this, according to WHO, antimicrobial resistance is con-
sidered one of the biggest threats to public health due to its
epidemiological impact. The WHO underlines how the
inappropriate use of antibiotics has led to the phenomenon
of antibiotic resistance. By using antibiotics in inappropri-
ate doses and timing, treating non bacterial infections with
antibiotics, using an intramuscular route when the oral
route is appropriate, not following the guidelines of pre-
scription or for inappropriate self-prescription or use of
antibiotics beyond the necessary. Some studies have shown
that in hospital 30-50% use of antibiotics used is inappro-
priate and that improving prescription determines a reduc-
tion of antibiotic resistance and related hospital infections
assistance. The final consequence of antibiotic resistance is
the reduction of effectiveness of antimicrobial therapies
puts at risk the anti-infective medical therapy that current-
ly allows us to treat prosthetic infections, infections in
severe oncological-haematological diseases and organ
transplants and more. If the current prescribing behaviors
and inappropriate use of antibiotics will not be changed, in
2050 the antibiotic resistance will cause more deaths from
infection than cancer. Hence the commitment to antibiotic
government programs (antimicrobial stewardship) in order
to improve: the prescription, with the use of optimal ther-
apy regimens, diagnosis, surveillance and prevention of
bacterial infections. All this with strategies of control of
infections and their transmission in acute and long-term
facilities; antimicrobial stewardship programs for anti-
infective drugs; re-evaluation of the therapeutic potential of
previous used anti-infective drugs; improvement of micro-
biological response times to reduce the duration of empir-
ical therapy; development of new antimicrobial molecules.
The American Society of Infectious Diseases (IDSA), in its
guidelines, highlights how the Antimicrobial stewardship
(AS) has a fundamental role in achieving prescriptive and
responsible appropriateness, not only for the individual
patient but for the whole general context of the ecosystem.
Moreover the activity of the Infectious diseases department
in the hospital and on the territory can help to sensitize the
clinicians to follow the principles for the correct use of
antibiotics with appropriate use that requires an adequate
microbiological study before the prescription; prescription
of the drug in the presence of infection and not coloniza-
tion; correct administration by dose, time and duration in
respect of pharmacokinetics and pharmacodynamics of the
molecule (PK/PD); de-escalation of therapy based on
microbiological tests and clinical parameters; optimal sur-
gical prophylaxis by choice, time of administration and
duration (82). 
MANAGEMENT OF CHRONIC PROSTATITIS/CHRONIC
PELVIC PAIN SYNDROME
(Florian ME Wagenlehner) 
CP/CPPS is a not well defined entity. In everyday clinical
practice frequently the diagnosis is based upon pain symp-
toms in the abdomen or pelvis region radiating to adjacent
areas and might be accompanied with lower urinary tract
symptoms. Painful prostate on palpation is also frequent-
ly described without any standardization of the investiga-
tion. Usually rudimentary diagnosis is done, if at all
including a urinalysis and possibly a urine culture. No fur-
ther refined diagnosis is made and almost always pro-
longed and multiple antibiotics courses are prescribed,
sometimes alpha blockers, or pain medication is added.
The difficulties in the management of CP/CPPS arise from
the fact that it is a multifactorial condition, with diverse eti-
ologies. So very different circumstances might lead to the
same clinical picture, but possibly warrant different diag-
nosis and treatment. There is no objective diagnosis, such
as a histology, that can proof the condition. There is no bio-
marker that can be used for diagnosis or follow up of
patients, and there is lack of novel treatment strategies tak-
ing into account pathophysiological pathways.
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In terms of diagnosis there is an agreement that infection
should be ruled out by localization tests, as described
early by Stamey (1). To what extent ejaculate investiga-
tions could be beneficial is not entirely clear. Ejaculate
testing is frequently performed on routine examinations
heading for mere culture, which frequently provides
contamination samples, or in other words reflects the
microbiome of the external genitalia. However “next gen-
eration” investigations, such as cytokine analysis, cyto-
logical typing of immune cells etc., that could help strat-
ifying the immune response can nowadays be performed
in clinical routine (83). Epigenetic changes are frequent-
ly seen in chronic inflammatory diseases and should be
investigated according to systemic and compartment-
specific signals for epigenetic dysregulation of inflamma-
tory factors. By doing so a significant association with
systemic and local epigenetic inactivation of a mast-cell
recruiting molecule CXCR4, the receptor for CXCL12
was identified (83). The search for biomarkers should
include various pathways, including hormonal pathways
(84). In one study elevated local estrogen levels associat-
ed with an epigenetic down-regulation of the estrogen
receptors was identified. Investigating estrogen levels in
semen could therefore serve as a promising biomarker to
select patients for estrogen targeted therapy (84).
As pain is the main driver of reduced quality of life in
patients suffering from CP/CPPS (85), novel therapeutic
substances for the treatment of pain would be therefore
be highly interesting to test. Anandamide is a cannabinoid
(CB) produced on demand in response to elevated intra-
cellular calcium levels in post-synapse. It is an endoge-
nous agonist of the CB1 receptor which exerts potent
inhibitory effects on pre-synaptic glutamate release. The
fatty acid amide hydrolase (FAAH) is involved in the enzy-
matic regulation of anandamide and the inhibition of
FAAH elevates levels of anandamide in hyperexcited
synapse and potentially could reduce pain perception. In
a phase 2 study a peripherally active FAAH inhibitor
ASP3652 was investigated in CP/CPPS patients, as inhibi-
tion of FAAH is hypothesized to reduce the excitability of
urinary tract afferents including nociceptors (86). The
results of the study however did not show efficacy of ASP
3652 on pain symptoms in patients with CP/CPPS (86).
Most monotherapy studies in general have not been suc-
cessful, since CP/CPPS is a multifactorial disease with
different pathophysiological causes. A phenotyping
approach, the UPOINT concept, has therefore been rec-
ommended (6). This concept includes a multimodal
therapy for CP/CPPS in phenotyped patients, where each
identified phenotype according to the enlarged
UPOINTS classification is treated separately (87). Using
such a treatment concept, a clinically appreciable reduc-
tion of ≥ 6 points of the total NIH-CPSI score was
achieved in 77.5% of patients subjected to combination
therapy for a period of 6 months (87).
ROLE OF MULTIMODAL THERAPY FOR TREATMENT
OF CHRONIC PROSTATITIS
(Giorgio I. Russo, Gaetano Larganà)
Prostatitis is considered the “black sheep” of the prostate
family of disease, due to difficult to understand its caus-
es and its definitive therapy. It can be considered one of
the challenges that urologists have to face. In the last
decade, in fact, Google trend showed how the term “pro-
statitis” has been looking several times more compared to
the past, like prostatitis and therapy, like prostatitis +
phytotherapy and Serenoa repens. What kind of therapy
urologists could use against prostatitis? First of all, in
case of diagnosis of prostatitis, antibiotics are the first-
line agents for the treatment of CP, for 4-6 weeks.
Penicillin, fluoroquinolone, third-generation cephalo -
spo rin, macrolides could be used for CP/CPPS. If patient
has voiding low urinary tract symptoms (LUTS), alpha-
blockers for 4-6 weeks are also used. The use of alpha-
blockers demonstrates an average NIH-CPSI total score
reduction, an average pain e average voiding symptoms
reduction with an increase of quality of life (88). If pain
is present, simple analgesics +/- non steroidal anti-inflam-
matory drugs (NSAIDs) can be used. Different studies
compare the use of rofecoxib and celecoxib against
placebo. They demonstrate a pain reduction and a better
quality of life (89). Unfortunately, long-term use of anti-
inflammatory agents for CP/CPPS is limited by compli-
cations due to side effect profile, moderate effect on
symptoms (predominantly pain) and lack of data for
their use. Improvement of results has instead been
reached by the contemporary use of alpha-blockers,
antibiotics and anti-inflammatory (90), showing a better
control of prostatitis symptoms than use of a single drug.
In fact, unfortunately, no efficient monotherapeutic
option is available. The best evidence-based manage-
ment of CP/CPPS is a multimodal therapeutic approach
addressing the individual clinical phenotypic profile
(91); antibiotics, alpha-blockers and anti-inflammatory,
although they have an effect on the disease, cannot be
recommended as first-line monotherapy but could be
considered in a multimodal therapeutic regimen.
A different and new point of view in the treatment of
CP/CPPS is to considered phytotherapy. It could be rec-
ommended as primary therapy or in association with other
drugs to treat CP, because of their few side effects. The use
of quercetin (500 mg twice a day), in man with Chronic
pelvic pain syndrome, show a better control urinary symp-
toms, a lower symptoms duration and a better quality of
life against placebo (92). Cernilton, a pollen extract, show
a better control of pain and a 25% decrease in NIH-CPSI
score, with better quality of life against placebo, in
CP/CPPS patients (93). Pollen extract was studied against
placebo also in association with vitamins (Deprox 500) for
pain relief: after only 1 month from start of therapy it was
observed a decrease of NIH-CPSI score, although IPSS
remain constant.  Most important was the comparison
between Deprox 500 mg and Ibuprofen 600 mg for early
pain relief. Pollen extract demonstrated a better quality of
life and a major decrease in NIH-CPSI score, avoiding all
the side effect of the continuous use of NSAIDs like
ibuprofen. Eviprostat has an identical effect compared to
pollen extract in patients with CP/CPPS. IPSS total score,
IPSS storage score, IPSS voiding score after 4 and 8 week
of treatment with Cernilton or Eviprostat showed no stati-
cally difference in results from baseline. Another studied
phytotherapy drug is Serenoa repens. Profluss, an associa-
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tion of Serenoa repens plus selenium and lycopene has bet-
ter results in IPSS score, Qmax score than Serenoa repens
alone. In the last years other drug associations were stud-
ied for the treatment of patients with chronic prostatitis.
An Italian study reported about the association between
curcumin and Calendula (Riflog) versus placebo. The
results were encouraging, with a reduction of the NIH-
CPSI score and changes of peak flow, IIEF-5, VAS and
PEDT. Moreover, as already mentioned before, multi-
modal therapy has greater effectiveness than a single ther-
apy. Riflog, in association with alpha-blocker and antibi-
otics, improves quality of life, Qmax and reduced Santorini
ectasia and number of Stamey positive patients. At last
Calendula officinalis could be another phytotherapy drug
used in prostatitis, exploiting the numerous effect already
studied and know, like antiflammatory, antioxidant,
antiedematous or analgesic effects.
PROSTATITIS AND INTESTINAL DISEASES
(Clara Maria Granatieri)
The association of CP/CPPS syndrome with intestinal
symptoms has been described in the literature. In our
experience out of 232 patients suffering from prostatic
inflammation, 146 (63.2%) frequently exhibited alter-
ations of intestinal function (alternating constipation and
diarrhea, abdominal pain and bloating) and previous uri-
nary infections. The study of functional bowel pathologies
(Irritable bowel syndrome - IBS, IDP) has focused the atten-
tion on the intestinal microbiota. The interaction of bacte-
rial intestinal flora interaction with food is the basis of
many phenomena that influence the state of health or ill-
ness. In fact the microbiota, according to its composition
and by means of the products of bacterial metabolism,
influences the metabolic, immune and inflammatory
response of the organism (94). An anti-inflammatory
action occurs at the level of Toll-like receptors (TLR); pro-
biotics are able to regulate the balance if intestinal flora, so
the TLR can correctly distinguish dangerous antigens from
those that must be tolerated. Reduced intake of fiber in the
diet alters the intestinal microbiota, with reduced bacteri-
al production of compounds modulating the immune
response. To regulate the intestinal flora, proper nutrition
is therefore crucial. Numerous studies attest the important
role of diet in proper formation and maintenance of the
intestinal microbiome. Epidemiological studies have cor-
related the increase of inflammatory pathologies with
"modern" nutrition, the so called "Western diet" that is the
intake of large quantities of red meat, simple carbohy-
drates, fat, refined cereals and poor portions of vegetables,
fruit and fish. The damages caused by this diet are due to
the inability of the human genome to adapt to rapid
changes in the environment, especially diet (95). 
The "Mediterranean diet” is more similar to that of our
ancestors and is considered the standard diet for human
health (96). The complex cumulative nutritional effects of
the foods rather than the intake of single macronutrients
(proteins, carbohydrates, fats) and micronutrients (miner-
als and vitamins) play an important role in the protective
effect of the Mediterranean diet (96).
The diet has its effects on inflammation both by direct
action on the cells and regulation of the composition of
intestinal flora. Foods directly influence the immune
response and therefore inflammation of intestinal and
extra-intestinal tissue. Intestinal cells, in particular ente-
rocytes and immunocompetent cells, are equipped with
complex systems for “sensing” foods and respond to them
(97). In fact, intestinal cells express pattern recognition
receptors, such as the TLR, the NOD-like receptors (NLR)
and the Leucine rich alpha-2-glycoprotein1 (LRG1). They
recognize both pathogen associated molecular patterns
(PAMPs) and damage associated molecular patterns
(DAMPs). In fact an inflammation in the absence of
pathogens can occur in all the tissues, in response to a
wide range of stimuli, which cause stress and damage to
cells (sterile inflammation) (98). In the sterile inflamma-
tion some nutrients are able to cause conditions of cellu-
lar stress. Various DAMPs are released from damaged
cells and activate immune cell receptors (TLR, NLR,
LRG1) which were originally identified as PAMPs sen-
sors. In particular DAMPs lead to the assembly of a
cytosol protein complex, called inflammasome, which
activates the caspase-1 protease with consequent activa-
tion and secretion of IL-1beta. The nutrients can there-
fore interact with the intestinal epithelium and the cells
of the system immune, as do viruses, bacteria and other
environmental factors, activating the same pathways of
cellular signals that activate or reduce inflammation.
MICROBIOTA-EUBIOSIS-DYSBIOSIS
(Roberto Colombo)
The pool of bacteria and other microorganisms (viruses
and prokaryotes) that lives in coexistence in the human
intestine is called intestinal microbiota (99-107). 
The Microbiota is made up of 100 trillion bacteria in a
balanced composition of several divisions (Phyla), genera
and bacterial species, which can act as
– "commensals" that do not provide any benefits or harm
to the guest
– "symbionts" mainly Bifidobacteria and Lattobacilli with
probiotic activity
– "pathobionts" resident bacteria with potential for patho-
logical induction.
The composition and concentration of bacterial genera
and species differs in the various segments of the gas-
trointestinal tract from 102 in the stomach to 1012 in the
colon.                           
The intestinal microbiota implements 3 probiotic func-
tions:
– protective function against pathogenic bacteria from
the outside and pathobiont bacteria: this action is car-
ried out by anti-bacterial activity (bacteriocins) for
space and nutrient competition and for slight acidifi-
cation of the environment to inhibit the growth of
pathogenic bacteria
– metabolic function by synthesis of vitamins, decom-
position of bile acids and above all production of
short-chain, butyric, propionic and acetic fatty acids
(butyrate is the trophic factor for intestinal mucosal
cells)
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– probiotic bacteria, especially Bifidobacteria and
Lattobacilli, that also have the function of modulation
of the intestinal immune system (GALT: Gut Associated
Lymphoid Tissue, 60% of the entire intestinal system);
this occurs because the products of probiotic bacteria
(lipopolysaccharides, peptidoglycans) stimulate specif-
ic receptors of the dendritic cells of the intestinal
mucosa which, for this stimulation, produce
Interleukin 10 which stimulates the regulatory T lym-
phocytes that implement the modulation of the GALT.
In addition, the intestinal epithelial cells produce a
mucous layer that covers the intestinal surface, consist-
ing of mucin polymers that act as nutrients and sites of
adhesion of probiotic bacteria. 
The balanced microbiota is in a state of “eubiosis” with
welfare functions for the whole organism. The qualitative
and quantitative alteration of the Microbiota is called
“dysbiosis” which, by altering the probiotic functions,
causes invasive intestinal diseases and correlates with
numerous systemic diseases. The causes of dysbiosis in
adults are determined by drugs, stress, wrong diet, bad
lifestyle, infections and food intolerances. 
Dysbiosis can be "deficienct" when caused by drugs or
stress or wrong fiber-free diet, or "stagnant" or "putrefac-
tive" when foods such as fats and red meat that stimulate
the flora to putrefactive activity prevail in the diet or, on
the other side, when fermentable foods (legumes, citrus
fruits, etc.) are excessive.
A diagnostic innovation regards the evaluation of the
dysbiotic action of colina (by excess of eggs) and carni-
tine (by excess of red meat). The dysbiotic flora induced
by excess intake of these substances produces
Trimethylamine Oxide (TMAO). This product stimulates
the formation of foam cells, inflammatory cells with oxi-
dized LDL, which stimulate the formation of atheroma-
tous plaque. TMAO represents an important new cardio-
vascular risk marker. 
The presence of dysbiosis mainly determines low-grade
inflammation with hyperstimulation of the immune sys-
tem and endotoxaemia, because the dysbiotic bacteria
produce substances that stimulate the receptors of den-
dritic cells inducing the production of inflammatory
interleukins with increased reactivity of T17 and T1 lym-
phocytes to pro-inflammatory action.
Dysbiosis, as well as other stimuli, such as gluten, deter-
mine the secretion by intestinal cells of the zonulin pro-
tein, which acts on the "tight junctions" of the intestinal
epithelial cells, causing increased intestinal permeability.
Dysbiosis, zonulin and consequent low-grade inflamma-
tion are the pathophysiological causes of the numerous
diseases related to the alteration of the microbiota. The
gastrointestinal pathologies are at first local (as leaky gut
syndrome) developing food intolerances, subsequently
they can worsen when there is a concomitant alteration of
the balance of the brain intestinal axis (psychosocial
hypersensitivity/excess of catecholamines) with IBS or vice
versa when polymorphisms predisposing to inflammation
cause the onset of a chronic inflammatory bowel diseases
(IBD). Dysbiosis can cause, for the pathophysiological fac-
tors mentioned above, systemic diseases such as diabetes
mellitus (as the produced inflammatory factors as inter-
leuchin-6, IL6, and Tumor Necrosis factor, TNF) determine
insulin resistance) or cardiopathies (due to production of
Trimethylamine Oxidize, TMAO) or allergies in atopic sub-
jects or autoimmune diseases secondary to synovial migra-
tion of inflammatory cells or depression due to reduction
of serotonin production by intestinal cells or cystitis and
vulvovaginitis in the female caused by migration of patho-
bionts bacteria of the dysbiotic intestinal flora. The alter-
ation of the microbiota is also related to obesity because of
the alteration of the relationship between Bacteroidetes
and Firmicutes that are the two main bacterial divisions
that make up 90% of the intestinal microbiota whose rela-
tionship represents a main biodiversity index. This ratio is
normally about 0.8, but in obesity it is changed with an
increase of Firmicutes that determines an increase in the
ability to recover energy from the diet due to increased
carbohydrate metabolism.
Low-grade inflammation, increased intestinal permeabil-
ity, presence of pathobionts bacteria and trans-parietal
migration may also be involved in the pathogenesis of
acute and chronic prostatitis. Repeated antibiotic thera-
pies that often accompany the clinical process of uro-
genital and prostatic infections represent a factor that
repeatedly feeds the dysbiosis related to these diseases
highlighting the importance of the therapy with probiot-
ic bacteria to restore the eubiosis and stop the vicious
circle of dysbiosis-urogenital infections. Bacterial therapy
is based on the use of live probiotic bacteria, with correct
taxonomic identity according to Qualified Presumption of
Safety (QPS) and International Depository Authority (IDA)
status. The timing of administration of bacterial therapy
should never be less than 21 days and the amount of live
bacteria should never be less than one billion daily.
HYDROCOLONTHERAPY: THERAPEUTIC OPTION IN
PATIENTS WITH CHRONIC PROSTATITIS AND DYSBIOSIS? 
(R. Giuberti)
The investigation on the intestinal microbiota in the
CP/CPPS has detected less alpha diversity of the microbio-
ta respect to controls (lower presence of Prevotella genus,
to which an anti-inflammatory role is recognized) (108).
The microbiota can generate, amplify and maintain a sys-
temic or a local inflammatory condition, causing, as a
consequence, a possible painful state, that could have a
role in the etiology of the CP/CPPS (109). 
Dysbiosis with persistence of pathogenic noxae can acti-
vate mast cells causing chronic inflammation. Bacteria
belonging to the phylum Proteobacteria have an outer
membrane composed mainly of lipopolysaccharides (LPS)
that stimulate monocyte activity through various steps.
LPS are anchored to the external membrane of the bac-
teria and are released once bacteria die provoking a reac-
tion from the organism with possible increase of the vas-
cular permeability and consequent inflammatory state.
They increase intestinal permeability through an intra-
cellular mechanism that involves the up-regulation of
TLR-4, which depends on the membrane expression of
CD-14 (110). TLRs are receptors expressed on the mem-
brane of sentinel cells such as macrophages, dendritic
cells and antigen-presenting cells (APC). In particular,
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TLR-4 is crucial in the recognition of LPS. The activation
of TLRs in the intestinal microbiota by the presence of
pathogenic microorganisms induces the triggering of the
mechanisms of innate immunity and the onset of inflam-
matory phenomena. The condition of dysbiosis leads to
an indirect dysfunction, therefore not primary but sec-
ondary, of the intestinal epithelia barrier which creates a
way of entry into the organism, through the blood, of
bacteria, giving rise to phenomena of bacterial transloca-
tion (bacteria in places other than those of origin). The
alteration of intestinal permeability, due to lactobacilli
and bifidobacteria deficiency, leads to loss of integrity of
the mucosal barrier, passage of antigens in the submu-
cosa and immune activation. The activation of the mast
cells maintain an up-regulation with acute and chronic
pro inflammatory consequences. 
Recent studies have widely established that mast cells
can also respond to non-IgE dependent stimulation. In
these cases, mast cells appear to undergo ultrastructural
alterations of the granular nucleus, that appears dense
with electrons, without the classic evidence of degranu-
lation that is related to an increase of IgE. A condition of
chronic mild inflammation is developed that reverber-
ates at the intestinal, prostatic and vaginal level. 
The best known triggers of this alternative activation
path include bacterial toxins, neurotransmitters and
stress that may be involved in the pathophysiology of
IBS. Patients with IBS have a 150% increase in mast cells
compared to a control group. 
The involvement of mast cells in abdominal pain of
patients with IBS has been widely demonstrated, in par-
ticular the presence of activated mast cells near the nerve
endings, is related to the intensity and frequency of
abdominal pain. Mast cells represent the most active sen-
tinels towards the external environment having a high
quantity of receptors that can be activated by allergens
such as food, drugs, cytokines. 
The mast cell can acts both by paracrine signaling, espe-
cially for the presence of pseudopods which can extend
the inflammatory response to blood vessels and nerve
endings, and autocrine signaling to itself because it has
receptors to the substances that it releases. 
Consequently, if the causes of its activation are not
removed, the inflammatory process can become chronic. 
Some studies have shown that dysbiosis can cause the
release of zonulin which leads to the passage of endolu-
minal contents through the epithelial barrier with conse-
quent release of pro-inflammatory cytokines.
Zonulin is a protein that regulates the junctions of the
intestinal walls and ,if in excess, loosens them, favoring
a state of intestinal permeability. It was first described in
2000 by Fasano et al. at the Celiac Research Center of the
University of Maryland School of Medicine. who focused on
the role of zonulin in intestinal tissues during the acute
phase of coeliac disease (111).
The values of zonulin may represent the reference param-
eter for the evaluation of the extent of the intestinal mucosa
alteration and the consequent state of its permeability. The
values found are significant of the progression of the
inflammatory condition and correlated with clinical symp-
toms and can be a guide of the treatment.
In 22-31% of patients with chronic bacterial prostatitis
and chronic pelvic pain syndrome a condition of IBS can
increase the severity of the pain symptom in the follow-
ing regions: perineum, supra-pubic region, testes, penis,
pelvis, inguinal region, rectum, pain in urination, pain
during ejaculation and neuropathic pain (1). 
Accordingly, the therapeutic approach could aim at
restoring the intestinal microbiota through the examina-
tion of the stool, the rebalancement of the microbiota, an
adequate diet and the application of hydrocolon therapy
to eliminate bacterial over-growth and pro-inflammatory
toxins generated by lipopolysaccharides (LPS). 
The application of hydrocolon therapy in chronic pro-
statitis is based on the ability of a gentle and targeted
flow of water entering the intestine during the treatment
sessions to regenerate the intestinal environment,
through the elimination of inflammatory components
that reside in the microbiota. The regularity of the
incoming flow through the targeted maneuvers of the
operator, which operates on the water flow and pressure
parameters in an appropriate manner, allows to create an
environment favorable to the regrowth of a microbiota
rich in lactobacilli and bifidobacteria that is essential to
maintain the intestinal mucosal integrity and to guaran-
tee an effective motor peristalsis. 
The application of hydrocolon therapy in vulvodinia has
achieved a significant improvement of pain with con-
comitant decrease of inflammatory parameters. It is
desirable that the application of the technique on sub-
jects with CP/CPPS can lead to an equally significant
benefit, in association with therapies targeted to the
restoration of a balanced intestinal microbiota and func-
tional to the elimination of the noxae pathogenic of the
inflammatory activation that can support the syndrome. 
The restoration of intestinal eubiosis, through the target-
ed integration of probiotics, guided by the examination
of stools, a healthy and balanced dietary approach aimed
at maintaining a balanced microbiota and hydrocolon-
therapy sessions can represent a new integrated thera-
peutic approach, centered on the multi-factorial biologi-
cal etiology, that support a chronic inflammatory process
as the CP/CPPS could be defined.
GYNECOLOGICAL INVESTIGATION OF THE PARTNERS
OF CHRONIC BACTERIAL PROSTATITIS PATIENTS
(Elisabetta Massa)                     
The human vagina is the location of an ecosystem whom
different participants (local microbial populations, local
environment and host’s characteristics) always are in a
dynamic equilibrium. This ecosystem is open to contami-
nations both from the external and from the intestinal envi-
ronment, so it is susceptible to colonization from microor-
ganism that can be symbiotic or pathogenic according to
their bacterial counts and to their ability to modify the vagi-
nal homeostatic mechanisms. All the participants to vaginal
ecosystem (vaginal epithelium, pH, glycogen and lacto-
bacillary flora) are modified along the different ages of a
woman due to different hormonal production. A high
oestrogen production, such as during puberty or pregnan-
cy, stimulates the vaginal cells to proliferation and the
glycogen storage. Moreover, glycogen facilitates the lactic
243Archivio Italiano di Urologia e Andrologia 2018; 90, 4
Multidisciplinary approach to prostatitis
Magri_Stesura Seveso  15/01/19  11:31  Pagina 243
Archivio Italiano di Urologia e Andrologia 2018; 90, 4
V. Magri, M. Boltri, T. Cai, et al.
244
acid production and the lowering of vaginal pH. Moreover,
the lactobacillary flora, divided in five groups following the
predominant species (L. crispatus, L. gasseri, L. iners, mixed
group e L. Jensenii) (112), has a protective role because it
stops the pathogens’ growth and their cohesion (113). All
these mechanisms are the first line in vagina’s defences.
Furthermore, menstrual cycles , sexual activity, antibiotics
or oral contraceptives assumption can modify the vaginal
macrobiotic. The vaginal microbiota has an active role in
the mechanisms of conception, pregnancy and delivery
(time and modality) (114). In presence of disruption of
vaginal homeostasis (due to alteration of control mecha-
nisms or to different susceptibility of the host), there are
vaginal infections (vaginitis) due to attack from external
pathogens or dysbiosis (vaginosis) due to a quantitative
redistribution of local flora. For a correct diagnosis, it is
important to evaluate the patient’s clinical history, charac-
teristic signs or symptoms, vaginal pH value, the fish’s odor
test, the microscopic exam with or without staining and a
cultural/molecular test. Partners of 399 patients suffering
from Chronic Prostatitis or Chronic Pelvis Pain
Syndrome: who underwent to a vaginal, cervical or ure-
thral swab showed the same pathogen isolated in male
patients, namely Enterobacteria, Uraplasma uralyticum,
Gardnerella vaginalis and Chlamydia. Moreover, clinical
characteristics of vaginal infections, their association
with sexual transmitted diseases (STD), the gynaecological
and reproductive consequences and the obstetric com-
plications have to be analysed (115-117). 
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